PedAM
Pediatric Disease Annotations & Medicines
| Disease | schizophrenia |
| Symptom | C0013384|dyskinesia |
| Sentences | 11 |
| PubMedID- 21907089 | dyskinesia can develop in patients with schizophrenia in the course of the disease with or without the use of antipsychotics.in patients with psychiatric disorders other than schizophrenia tardive dyskinesia (td) can develop in patients treated with antipsychotics or other drugs with dopamine d2 blocking properties. |
| PubMedID- 21836674 | Padmavati studied differences in cerebral morphology in three groups-untreated schizophrenia patients with dyskinesia, without dyskinesia and normal subjects. |
| PubMedID- 22071797 | Objectives: to determine the effects of calcium-channel blocker drugs (diltiazem, nifedipine, nimodipine, verapamil) for treatment of neuroleptic-induced tardive dyskinesia in people with schizophrenia, schizoaffective disorder or other chronic mental illnesses. |
| PubMedID- 23918915 | The authors present a case of a 29-year-old woman who presented to a family medicine clinic for ongoing management of schizophrenia with noticeable tardive dyskinesia and complaints of neck and upper back pain. |
| PubMedID- 21612745 | Objective: the aim of the study was to survey the frequency of tardive dyskinesia (td) in patients with schizophrenia and its demographic and clinical correlates in selected asian countries. |
| PubMedID- 25866243 | Objectives: to determine the effectiveness of pyridoxal 5 phosphate (vitamin b6 or pyridoxine or pyridoxal phosphate) in the treatment of neuroleptic-induced tardive dyskinesia among people with schizophrenia and other related psychotic disorders. |
| PubMedID- 19740630 | Signs of striatal dopamine transporter density increase in association with improvement of tardive dyskinesia in a patient with schizophrenia, as demonstrated by a dat scan. |
| PubMedID- 23714238 | The finding of a 4-fold increased risk of spontaneous dyskinesia among persons with schizophrenia (but no exposure to an antipsychotic drug) compared with those without schizophrenia may be a result of the underlying disease, as suggested by others . |
| PubMedID- 25954194 | However, a 12 week double-blind placebo controlled study providing 2 g/day epa in schizophrenia patients with established tardive dyskinesia failed to demonstrate any anti-dyskinetic effects, although modest and transient benefits were seen in recent onset patients (emsley et al., 2006). |
| PubMedID- 25717485 | Tardive dyskinesia in patients with schizophrenia treated with olanzapine - results from a 20-month, prospective, open study under naturalistic conditions. |
| PubMedID- 26257524 | A subsequent review123 sought to determine the effects of bdzs on neuroleptic-induced tardive dyskinesia in people with schizophrenia or other chronic mental illness. |
Page: 1